Details of the Drug

General Information of Drug (ID: DMLV939)

Drug Name

AR1001

Synonyms

N-METHYLBENZYLAMINE; 103-67-3; N-Benzylmethylamine; N-methyl-1-phenylmethanamine; Methylbenzylamine; Benzylmethylamine; Benzyl(methyl)amine; Benzenemethanamine, N-methyl-; N-Benzyl-N-methylamine; Benzylamine, N-methyl-; N-Methy-N-benzylamine; Benzyl-methyl-amine; N-methyl-N-benzylamine; methyl benzylamine; N-Methyl(phenyl)methanamine; BENZYLAMINE, N-METHYL; N-benzyl-methylamine; N-methyl benzylamine; N-methyl-N-(phenylmethyl)amine; Benzylmethyl-d3-amine; NSC 8059; N-methylbenzenemethanamine; MFCD00008289; N-methyl-1-phenyl-methanamine; 7KN7F4X49E; NSC-8059; methylbezylamine; benzyl methylamine; benzyl-methylamine; HNMeBzl; N-benzylmethanamine; benzyl methyl amine; methyl-benzyl amine; EINECS 203-133-4; N-benzyl methylamine; N-methyl-benzylamine; N-methylbenzyl amine; N-benzyl methyl amine; N-benzyl-methyl amine; N-methyl -benzylamine; N-methyl benzyl amine; N-methyl-benzyl amine; (-)-methylbenzylamine; Methylbenzylamine, N-; omega-Methylaminotoluene; Spectrum_001362; AI3-26793; Methyl(phenylmethyl)amine; N-benzyl-N-methyl-amine; N-methyl-N-benzyl amine; Spectrum4_001764; Spectrum5_000347; Racemic methylbenzyl amine; N-methyl-benzenemethanamine; EC 203-133-4; N-(Phenylmethyl)methylamine; N-Benzylmethylamine, 97%; SCHEMBL2271; CHEMBL1338; UNII-7KN7F4X49E; KBioGR_002247; KBioSS_001842; MLS004773900; DTXSID9048439; KBio2_001842; KBio2_004410; KBio2_006978; NSC8059; (+)-2-Methylbutylp-aminocinnamate; STR02536; AR1001; AKOS000119094; CS-W007426; HY-W007426; SDCCGMLS-0066901.P001; NCGC00166047-01; SMR000112361; FT-0631560; M0164; EN300-18191; W-108843; BRD-K44558320-003-01-7; Q23978278; Z57327124; F2190-0316; InChI=1/C8H11N/c1-9-7-8-5-3-2-4-6-8/h2-6,9H,7H2,1H

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 3	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C8H11N
Canonical SMILES: CNCC1=CC=CC=C1
InChI: InChI=1S/C8H11N/c1-9-7-8-5-3-2-4-6-8/h2-6,9H,7H2,1H3
InChIKey: RIWRFSMVIUAEBX-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 7669
TTD ID: D1OM8E

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phosphodiesterase 5 (PDE5)	TTUZ196	NOUNIPROTAC	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05531526) A Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 Over 52 Weeks in Participants With Early Alzheimer's Disease (Polaris-AD). U.S.National Institutes of Health.
2	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight